FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13s - 16 or 15d - 16 of
the Securities Exchange Act of 1934
For the month of August, 2006
Acambis plc
(Translation of registrant's name into English)
Peterhouse Technology Park
100 Fulbourn Road
Cambridge CB1 9PT
England
(address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Forms 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information
contained in this Form also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934).
Yes No X
(if "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82- ).
Enclosure:
Notice of Results
Notice of results
Cambridge, UK and Cambridge, Massachusetts - 25 August 2006 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) will announce its results for the second
quarter ended 30 June 2006 on Wednesday, 13 September.
The results announcement will be released at 7.00 am BST. A conference call for
analysts will be held at 9.00am BST. For details, please contact Mo Noonan at
Financial Dynamics on telephone number +44 (0) 20 7269 7116. An instant replay
of the call will be available until 20 September 2006 on telephone number UK:
+44 (0) 20 7365 8427 and US: +1 617 801 6888. The pin code is 11414363.
An audio webcast of the call will also be available via Acambis' website at
www.acambis.com. The webcast replay will be available for 12 months until 12
September 2007.
-ends-
Enquiries:
Acambis plc
Lyndsay Wright, VP,
Communications and Investor Relations: Tel +44 (0) 1223 275 300
Financial Dynamics
Mo Noonan: Tel +44 (0) 20 7269 7116
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine and is
manufacturing emergency-use stockpiles of this investigational vaccine for the
US Government and other governments around the world. Acambis is establishing a
travel vaccines franchise through its US-based subsidiary Berna Products
Corporation, which markets Vivotif(R), the world's only licensed oral typhoid
vaccine, in North America. Acambis has other potential travel vaccines in
development and is also developing an investigational vaccine against the West
Nile virus, which has spread to 48 US States in the last seven years.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
About Acambis' NIAID contracts
Acambis has been awarded two contracts by the NIAID for the manufacture and
development of its MVA smallpox vaccine, MVA3000. The first contract, awarded in
February 2003, was for $9.2m. The second, awarded in September 2004, was worth
$76m and required clinical testing and manufacture of 500,000 doses of MVA3000.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and its Form 20-F, in addition to those
detailed on the Company's website and in the Company's filings made with the
Securities and Exchange Commission from time to time. These forward-looking
statements are based on estimates and assumptions made by the management of
Acambis and are believed to be reasonable, though are inherently uncertain and
difficult to predict. Actual results or experience could differ materially from
the forward-looking statements.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant Peptide Therapeutics Group has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
Date: 25 August, 2006 ACAMBIS PLC
By: /s/ Lyndsay Wright
Name: Lyndsay Wright
Title: VP, Communications and IR.